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Abstract: An important assumption of our current understanding of the mechanisms of 
carcinogenesis has been the belief that clarification of the cancer process would inevitably 
reveal  some  of  the  crucial  mechanisms  of  normal  human  gene  regulation.  Since  the 
momentous work of Bishop and Varmus, both the molecular and the biochemical processes 
underlying the events in the development of cancer have become increasingly clear. The 
identification of cellular signaling pathways and the role of protein kinases in the events 
leading  to  gene  activation  have  been  critical  to  our  understanding  not  only  of  normal 
cellular gene control mechanisms, but also have clarified some of the important molecular 
and biochemical events occurring within a cancer cell. We now know that oncogenes are 
dysfunctional proto-oncogenes and that dysfunctional tumor suppressor genes contribute to 
the cancer process. Furthermore, Weinstein and others have hypothesized the phenomenon 
of oncogene addiction as a distinct characteristic of the malignant cell. It can be assumed 
that cancer cells, indeed, become dependent on such vital oncogenes. The products of these 
vital oncogenes, such as c-myc, may well be the Achilles heel by which targeted molecular 
therapy may lead to truly personalized cancer therapy. The remaining problem is the need 
to introduce relevant molecular diagnostic tests such as genome microarray analysis and 
proteomic  methods,  especially  protein  kinase  identification  arrays,  for  each  individual 
patient.  Genome  wide  association  studies  on  cancers  with  gene  analysis  of  single 
nucleotide  and  other  mutations  in  functional  proto-oncogenes  will,  hopefully,  identify 
dysfunctional proto-oncogenes and allow the development of more specific targeted drugs 
directed against the protein products of these vital oncogenes. In 1984 Willis proposed a 
molecular  and  biochemical  model  for  eukaryotic  gene  regulation  suggesting  how  
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proto-oncogenes might function within the normal cell. That model predicted the existence 
of vital oncogenes and can now be used to hypothesize the biochemical and molecular 
mechanisms that drive the processes leading to disruption of the gene regulatory machinery, 
resulting in the transformation of normal cells into cancer. 
Keywords: oncogenes; gene regulation; gene transcription; transcription activator; targeted 
cancer  therapy;  signal  transduction;  carcinogenesis;  protein  kinase;  cell  cycle  control; 
steroid hormone action 
 
1. Introduction 
In the beginning, we could only speculate about the mysterious and seemingly incomprehensible 
processes within the human cell that govern gene regulation. Furthermore, an understanding of the 
deregulation of a cell’s normal gene regulation resulting in its transformation into a cancer was even 
more mysterious and challenging. We could only guess how a human gene is turned on or off. Our 
models of eukaryotic gene regulation consisted of vague diaphragms and marvelous, but nonspecific, 
terms that failed to reveal a unifying biochemical and molecular concept sufficient to explain how 
human  genes  are  regulated,  and  how  genomic  deregulation  becomes  the  pivotal  event  leading  to 
carcinogenesis  [1].  Although  we  now  have  an  impressive  understanding  of  the  general  processes 
involved in the transcription of eukaryotic cells [2], little did we realize that the beginning of our true 
understanding of such matters would come from a series of seemingly unrelated crucial discoveries.  
Peyton Rous discovered that he could induce tumor formation in chickens by cell-free extracts [3]. 
Rous sarcoma virus proved to be a retrovirus [4]. These retroviruses utilize their RNA genetic codes to 
generate complementary provirus DNA which subsequently is integrated into the host cellular DNA at 
random sites [5]. When new retroviral RNA is generated, it may contain additional sequences derived 
from the DNA of its host. This fused genetic product may contain host genomic sequences that are 
directly involved in normal host gene regulation. A retrovirus may choose to transmit these regulatory 
proto-oncogene sequences to other infected cells resulting in cellular neoplastic transformation. Bishop 
and  Varmus  concluded  that  the  Rous  sarcoma  virus,  in  fact,  had  hijacked  the  cell’s  regulatory  
proto-oncogene, converting its protein product into an oncoprotein [6]. Another crucial discovery was 
the realization that there was a tumor virus and protein kinase connection, and the fact that these 
oncoproteins contained tyrosine kinase activity [7,8]. Protein phosphorylation reactions play a significant 
role in a host of cellular processes [9–11]. Understanding the astounding fact that these oncogenic 
viruses achieved their neoplastic effect by capturing a critical host gene regulatory sequence with protein 
kinase ability, paved the way for new insights about not only normal eukaryotic gene regulation, but 
also presented a new and potentially profound way of looking at the origins of cancer [12].  
An incomprehensible amount of research has been achieved since the presentation of these central 
discoveries and concepts. The regulation of transcription by phosphorylation should be undisputed [13]. 
Yet, the previously proposed important role of phosphatase reactions in human gene regulation can no 
longer  be  ignored  [11,12,14–22].  We  now  understand  the  magnificent  role  of  proto-oncogenes  in 
normal cell growth and development [23]. There is an increasing understanding of the biochemical Int. J. Mol. Sci. 2012, 13               
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pathways leading from extracellular stimuli through the cell’s membrane and into the cell’s cytoplasm. 
This sometimes intricate signal transduction cascade inevitably must end within the nucleus, where 
vital  oncogenes  must  function  [24,25]. And we now know  that the most  common domain that is 
encoded by cancer genes is the protein kinase [26]. The efforts to clarify the normal mechanisms 
involved in cell cycle control have been equally fruitful in shedding light upon the dysfunctional 
events during the cell cycle of a cancer cell [27–29]. It is not surprising that there is indeed a connection 
between the cell cycle and cancer. It is the cell cycle process that leads to normal cell proliferation. An 
abandonment of such a normal process is the essence of the neoplastic process. For example, we will 
see how in particular the cancer process impacts the crucial regulatory machinery of the G1 phase of 
the cell cycle. 
Weinstein has proposed an insightful theory about the peculiar characteristics of the dysfunctional 
genomic activities of the cancer cell [30,31]. He has suggested that cancer cells become addicted to an 
overactive oncogene or a selective signal transduction pathway leading to activation of this dependent 
dysfunctional  proto-oncogene.  The  effect  of  some  recently  developed  molecular  targeted  cancer 
therapies may give clinical support to this notion [32]. Such a phenomenon would have an even greater 
significance if we assume that this event involves vital oncogenes. Such oncogenes would be the 
critical oncogenes that the cancer cell has become dependent upon for its survival. 
Demonstrating the mere existence of vital oncogenes is insufficient for our complete understanding 
of the neoplastic process. A significant obstacle still would remain. How would these vital oncogenes 
usurp the crucial normal gene regulatory mechanisms? As stated earlier, commandeering the normal 
cell cycle control mechanisms is mandatory. Yet, these vital oncogenes would have to accomplish one 
other fundamental process. There has to be a mechanism that allows their control of the chromatin 
modification events that lead to gene transcription. There is evidence that binding site recognition by 
transcription  activators  is  determined  by  chromatin  context  [33].  The  previous  knowledge  of  the 
importance of chromatin structure and function in the eukaryotic gene regulatory process is ancient 
and deep [12,34–37]. This is also true of the importance of the placement of linker histone H1 during 
gene transcription [38] and the effect of histone modifications in transcriptional regulation [39,40]. 
Willis suggested that the phosphorylation of linker histone H1 would be the crucial event leading to a 
change from heterochromatin to a less condensed state allowing access to consensus sequence-specific 
DNA binding sites by transcription activators such as vital oncogenes [12]. The subsequent confirmation 
of the effect of histone H1 phosphorylation on histone H1’s secondary structure and DNA condensation 
has well been demonstrated [41,42]. The relevance of such phosphorylation events cannot go unnoticed 
in the context of potential events during vital oncogene action within the nucleus. 
If vital oncogenes are indeed the true wardens of carcinogenesis, achieving their goals by usurping 
cell cycle control mechanisms and intruding upon the normal mechanisms of gene transcription that 
leads to an addictive dependence by cancer cells, then they shall become the Achilles heel that we have 
long sought after. They should become the target for the development of molecularly targeted cancer 
therapy.  Yet,  before  such  an  idealistic  world  can  exist,  we  must  first  develop  the  tools  and 
methodology needed to identify and isolate the oncogenic protein products of these entities. Although 
it is clearly recognized that cancer is a genetic disease [26], an even more appropriate perspective is 
that it is a disease of molecular dysfunction. This is so because the fact is that it is the molecular  
by-products  of  these  oncogenes  that  are  the  true  actors  responsible  for  the  seemingly  demonic Int. J. Mol. Sci. 2012, 13               
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transformation of beautiful biochemical cascades into wayward pathways of independent self-indulgence 
and host death. 
The  final  defeat  of  this  disease  will  occur  with  the  emergence  of  the  practical  applications  of 
genomics and proteomics [43]. There can be no greater impact on translational medicine then the 
knowledge gained from the completion of the human genome project. The identification of the human 
genetic landscape has directly allowed the development of high-throughput technologies that include 
genetic mapping and identification of potential target sequences involved in the neoplastic process. 
The  investigation  of  gene  expression  profiles  using  complementary  DNA  microarrays  is  rapidly 
dominating the initial efforts to understand critical alterations in the transcriptome that may reflect the 
distinct footprints of the consequences of the controlling effects of vital oncogenes [44,45]. But the 
supreme contribution this particular technology will play in our increasing knowledge of the cancer 
process will be the ability to directly identify the gene targets of transcription activating vital oncogenes 
such as c-myc [46].  
The multifaceted aspect of the applications of protein microarray technology belies its inevitable 
incomprehensibly important role in the future design and development of truly personalized targeted 
cancer therapy [47]. Signal transduction is the chosen biological mode by which the human cell reacts 
to its microenvironment, regulates its critical biochemical pathways, and alters the activities of its 
genes  [48].  Mass  spectrometry  proteomic  techniques  may  be  used  to  profile  signaling  proteins  in 
cancer cells [49]. But it is the evolution of special analytical mass spectrometry proteomic techniques 
that will make the greatest contributions to the development of the ultimate specific diagnostic tests 
and targeted therapies that will define personalized cancer care. The significant role of phosphorylation 
reactions in normal human cell function is now self- evident. Protein kinases account for nearly 2% of 
the human genome [50]. And one-third of all proteins in the eukaryotic cell are phosphorylated at any 
given  time  [51].  A  starting  point  is  the  analysis  of  the  phosphoproteome  in  normal  and  cancer  
cells [52]. Surely the identification of distinct phosphoproteins with characteristic function-altering 
phosphorylation patterns will identify the important role that these vital oncoproteins are playing in the 
cancer process [53]. It can be assumed that antibody-based proteomics will be the corner stone of this 
effort [54]. Ultimately, both genomic and proteomic techniques will be utilized routinely in the future 
to  decipher  the  molecular  and  pathophysiological  characteristics  of  the  individual  cancer  of  an 
individual patient. This will be the essence of true personalized cancer care. 
2. Gene Control by Phosphoproteins: A Basic Theory  
Although gene regulation in humans is complex, and much has been learned in the past two decades, 
the elementary theoretical foundation for understanding normal and abnormal human genome function 
has been previously presented [12]. This theory proposed the following. First, human gene regulation 
requires a specific but simple general mechanism for gene activation. Second, gene activation should 
be  achieved  by  a  reversal  of  non-specific  genomic  suppressive  processes.  Third,  both  genomic 
structure and biochemical events are crucial to the activation and deactivation of genes. The specific 
and most important biochemical events are phosphorylation reactions. Fourth, oncogenes usurp and 
mimic the  normal function of proto-oncogenes during carcinogenesis. Fifth, the existence  of vital 
nuclear oncogenes is predictable. Sixth, the phosphorylation of both DNA and RNA polymerase not Int. J. Mol. Sci. 2012, 13               
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only  plays an  important role  in  normal gene  regulation, but  the  phosphorylation of both  of these 
molecules  is  facilitated  during  oncogene  action.  Seventh,  dephosphorylating  reactions  and  protein 
phosphatases play an important role in cell regulation by proto-oncogenes and cell deregulation by 
oncogenes, as a result, suppressor proteins with phosphatase activity must exist. Eight, there will exist 
a host of dysfunctional proto-oncogenes with protein kinase activity. Ninth, the mechanism for viral 
transformation  of  eukaryotic  cells  duplicates  the  same  transformation  process  by  oncogenes  [55]. 
Tenth, steroid hormone receptors are phosphoproteins that function as nuclear transcription activators 
and regulate the human genome in the same manner as proto-oncogenes. 
The suggested general events that lead to normal gene transcription were described as follows: 
1  Nuclear proto-oncogene protein kinases are activated by phosphorylation. 
2  These phosphorylated activated protein kinases bind to recognition sites in the major groove of 
the DNA helix as it winds around the nucleosome core histones.  
3  A series of phosphorylation reactions mediated by these nuclear phosphoproteins and facilitated 
by histone H1 phosphorylation result in the displacement of histone H1 away from the site of 
gene activation eventually allowing access by the transcription initiation complex. 
4  The exposed DNA sequences are essentially promoter sites. 
5  The phosphorylation reaction cascade includes recruitment and phosphorylation of either DNA 
polymerase or RNA polymerase. 
6  The intact histone octamer that makes up the nucleosome core complex functions as a scaffold 
during gene activity. The model assigned a central role to nuclear phosphoproteins. 
We now know that phosphorylation reactions are the foundation of the signal transduction pathways 
that ultimately target transcription activators, their coregulators, and associated chromatin-modifying 
factors,  leading  to  their  phosphorylation  by  protein  kinases  or  dephosphorylation  by  protein 
phosphatases [56,57]. We also now know that chromatin modifying events are essential for normal 
eukaryotic  gene  regulation.  The  debate  continues,  however,  concerning  the  role  that  specific 
biochemical events such as acetylation and methylation must play in gene regulatory processes [58,59]. 
But  a  review  of  the  literature  overwhelmingly  supports  the  pivotal  role  played  by  histone  H1 
phosphorylation in transcription and replication in both normal and transformed cells [60–62]. Only 
within the past ten years has sufficient data been generated verifying the yin and yang roles protein 
kinases and protein phosphatases play both in normal cell function and the cellular events transpiring 
during carcinogenesis [15,19]. Furthermore, distinct nuclear protein phosphatase inhibitors of nuclear 
located  transcription  activators  have  been  identified  [17].  Surprisingly,  an  interesting  group  of 
phosphatases have been identified which control the MAP kinase cascade. These are dual specificity 
phosphatases a subclass of the protein tyrosine phosphatase gene superfamily with the capacity to 
dephosphorylate  the  critical  phosphothreonine  and  phosphotyrosine  residues  found  among  MAP 
kinases [18]. Only recently has evidence shown that protein tyrosine phosphatases can function as tumor 
suppressors [20]. A unique dual-specific phosphatase tumor suppressor gene has been identified [63].  
The transforming mechanisms for DNA tumor viruses have become increasingly evident also only 
recently.  As  will  be  discussed  later  for  vital  oncogenes,  tumor  viruses  with  dominant  acting 
oncoproteins exert their effects by interacting with key cellular targets resulting in the disruption of the 
normal controlling constraints placed on cell replication and gene transcription. The SV-40 large T Int. J. Mol. Sci. 2012, 13               
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antigen interacts with Rb, p53 as well as the pp2A phosphatase during transformation [64]. Likewise, 
research has revealed an interaction between SV-40 small T antigen and cyclin E resulting in an 
enhanced action of the cyclin-dependent kinase CDK2, a  key regulator in the passage of the cell 
through the cell cycle restriction point between G1 and the DNA synthesizing S phase [65]. SV-40 
small T antigen also has been shown to stimulate cyclin D1 promoter activity [66]. Cyclin D1 is the 
regulatory  protein  which  cyclin-dependent  kinases  CDK4  and  CDK3  depend  upon  for  their 
phosphorylation-driven activation to also allow passage of the cell completely through the G1 phase 
and into the S phase.  
Steroid hormone receptors and steroid hormone action have been the topic of intensive basic and 
clinical  research  for  decades.  This  nuclear  hormone  receptor  superfamily  contains  the  receptors 
associated with not only steroid hormones, but thyroid, vitamin D, and retinoid hormones as well. 
Many are ligand associated regulatory proteins. In fact, it is now clear that they all function as nuclear 
receptors by directly interacting within the region of the DNA response elements of target genes. 
Among  other  events,  we  now  know  that  some  hormone  receptors  have  the  capacity  to  recruit 
coregulators and interact by cross-talking to other signaling pathways. Even more revealing is the 
presence of some of the unique characteristics we now typically attribute to the cell surface protein 
kinase receptors involved in signal transduction during uncontrolled cell proliferation. For example, 
nuclear hormone receptors undergo a conformational change following ligand banding. The activation 
process of nuclear hormone receptors also often involves a formation of homodimers or heterodimers, 
the functional molecule. Of note, the recruitment of coactivator complexes to the target promoter 
during  gene  transcription  results  in  chromatin  decompaction  [67].  Steroid  hormone  receptor 
phosphorylation  is  now  well  demonstrated  and  understood.  Moreover,  the  exquisite  details  of  the 
physiologic dynamics of steroid receptor phosphorylation have become increasingly clear over the past 
few years [68]. It appears that the phosphorylation of the steroid receptor modulates a host of its 
functions,  including  its  stability,  nuclear  localization,  hormone  sensitivity,  DNA  binding,  and  
protein-protein  interactions  that  determine  the  specificity  and  extent  of  the  regulation  of  target  
genes [69]. In addition, unliganded estrogen receptor mutants may function as downstream targets of 
the MAP kinase transduction pathway resulting in their direct phosphorylation [70]. The implication of 
this  as  a  molecular  explanation  for  the  particular  virulence  of  estrogen  resistant  breast  cancer  is 
obvious. A yin and yang relationship is also evident in the relationship between estrogen receptors and 
protein  phosphatases.  The  transcriptional  activity  of  the  estrogen  receptor  is  halted  by  the 
dephosphorylating inhibitory effect of a protein phosphatase [71]. Finally, steroid receptor action is 
mediated by one of the same mechanisms proposed here for vital oncogenes. Cyclin-dependent kinases 
activity is needed as a coactivator [72]. All of the subsequent research supports the original concept 
that steroid receptors function like proto-oncogenes in normal cells. It therefore is further hypothesized 
that the molecular basis for the virulence of estrogen receptor negative breast cancer is a mutational 
change in the receptor affecting critical phosphorylation sites that result in hormone independence and 
the acquisition of the usurping characteristics of a vital oncogene. 
The continued validity of this phosphoprotein-driven model of the regulation of the eukaryotic 
genome should be based on the judgment of its relevance to what is currently known about the detailed 
biochemical and molecular aspects of human gene regulation, its testability, its compatibility with 
current knowledge, its predictive power, and its level of simplicity. Int. J. Mol. Sci. 2012, 13               
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―A theory is a good theory if it satisfies two requirements: It must accurately describe a large class 
of observations on the basis of a model that contains only a few arbitrary elements, and it must make 
definite predictions about the results of future observations [73].‖(Figure 1) 
Figure 1. Biochemical mechanisms in vital oncogene action. The oncoprotein products of 
vital oncogenes are the ultimate end targets of the cancer cell’s signaling pathways. Their 
cellular activities occur within the nucleus. 
 
3. The Role of Cyclin-Dependent Kinases and the pRB Protein in Cell Cycle Control 
A  defect  in  the  normal  cell  cycle  control  mechanisms  is  an  essential  component  of  
carcinogenesis [74]. The normal eukaryotic cell cycle consists of a series of well-orchestrated events 
ending in the production of two daughter cells. The stages of the eukaryotic cell cycle have been 
known for some time [75]. The cell cycle is composed of four phases (Figure 2). The entire process 
consists of two critical steps. During the S phase DNA is replicated. This ultimately leads to the M 
phase during which time cell mitosis occurs allowing the separation of duplicated chromosomes. The 
other two phases consist of gap periods. During G1 the cell prepares all of the necessary machinery 
needed  for  DNA  replication.  Following  DNA  replication  a  second  pause  occurs.  It  is  during  this 
second gap (G2) that the cell now prepares all the necessary machinery for cell division. But not all 
cells continue through this process. Some sidestep into a resting or quiescent phase designated G0 
where they may remain in a fully differentiated state. Cells may exit this state and re-enter the cell 
cycle as a result of internal or external stimulating events. It is crucial that the processes that drive the 
cell through its cell cycle are securely and efficiently regulated. The heart of this time-controlled 
mechanism lies at designated stop checkpoints that are the gatekeepers for the transitions between the 
phases of the cell cycle. These are the restriction points controlled by a family of protein kinases 
designated  cyclin-dependent  kinases,  CDKs  [76–78].  Cyclin-dependent  kinases  CDK4  and  CDK6 
regulate passage of the cell cycle through the restriction check-point (R) placed between the G1 and  
S interface. Cyclin-dependent kinase CDK2 later facilitates the transition process (Figure 2). If the  Int. J. Mol. Sci. 2012, 13               
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R checkpoint is usurped, it follows that the cell may inappropriately proceed through the cell cycle 
repeatedly. This is the classical cellular behavior found in cancer.  
Figure  2.  Usurpation of cell cycle control and transcription by vital oncoproteins. The 
oncoprotein  products  of  vital  oncogenes  could  enhance  the  cyclin-dependent  kinase 
phosphorylation activities resulting in phosphorylation of the Rb suppressor protein and 
histone H1. 
 
At least 11 mammalian CDKs have been identified [77]. They are the key regulators of the cell 
cycle [79]. These small molecules consist of little more than the catalytic core common to all protein 
kinases. Their enzymatic activation is completely dependent upon the binding of a regulatory cyclin 
subunit, but full activation requires the phosphorylation of a threonine residue residing near the CDK’s 
active site. Several regulatory cyclin proteins have been identified. Cyclin D is specifically associated 
with CDK4/6 while cyclin E regulates CDK2. During the cell cycle, the levels of the cyclin regulatory 
proteins rise and fall at the appropriate time while the levels of the CDKs remain the same. CDK7 
plays a distinct role. It is designated as a CDK-activating kinase (CAK) that phosphorylates other 
CDKs [80,81]. Because of this vital role, it follows that any event that could usurp this protein’s 
function in the cell cycle could result in the command of a crucial process in cell cycle regulation. 
Cyclin-activating kinase CDK7 therefore potentially regulates all of the phosphorylation activities of 
CDK4/6 and CDK2. The essential roles of CDK4/6 and CDK2 are to control cell cycle progression 
through phosphorylation of proteins that function at specific cell cycle stages. This includes the protein 
produced by the retinoblastoma tumor suppressor gene, pRb [82]. The CDKs in turn are regulated by a 
host of inhibitory proteins. Some of these cyclin-dependent kinase inhibitors interact with the CDK4/6 
complex to block kinase activity during G1 [83,84]. Deregulation of the normal functions of CDK and 
cyclin is associated with the development of cancers in humans [85–93]. Int. J. Mol. Sci. 2012, 13               
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The pRb tumor suppressor protein is the master break shoe preventing the progression of the cell 
completely through the G1 phase of the growth cycle and into the S phase [94,95] (Figure 2). Only the 
unphosphorylated  Rb  protein  has  this  functional  capacity.  It  achieves  this  by  binding  to  E2F 
transcription factors. The binding of the unphosphorylated Rb protein to E2F halts the binding of E2F 
to not only its consensus promoters, but also the promoters of such proto-oncogenes as c-myc and  
c-fos. E2F in turn activates the expression of cyclin E and CDK2 which normally further promotes the 
progression of the cell through the latter part of the G1 phase and well into the S phase. It is the state of 
the phosphorylation of pRb that determines its affinity for E2F. This affinity is greatest when pRb is 
hypophosphorylated. As expected, phosphorylation of pRb is maximal at the start of the S phase and 
lowest after mitosis. Furthermore, the phosphorylated Rb protein has the capacity to stimulate DNA 
polymerase alpha [96]. A loss of normal pRb function means the loss of control over the cell cycle.  
One  more  crucial  interaction  remains.  In  the  normal  cell  cycle  both  CDK2  and  CDK  4/6 
phosphorylate pRb which eliminates its inhibitory function on E2F and enhances its ability to stimulate 
DNA polymerase [96–98]. The overall processes of normal cell cycle control can now be summarized 
from these facts. Cyclin dependent kinases 2 and 4/6 are the proteins of interest here. They control cell 
cycle progression by phosphorylating the retinoblastoma tumor suppressor protein. The Rb protein 
now in a phosphorylated state loses its inhibitory binding capacity over E2F. The E2F-Rb protein 
complex dissociates releasing the two active components—an active transcription factor, E2F that 
promotes expression of cell-proliferation genes, and a phosphorylated Rb protein that stimulates DNA 
polymerase alpha leading to DNA replication (Figure 2). There are several superb reviews of these 
concepts [28,74,94,99]. 
4. Genomic Structure and Epigenetic Regulation 
Unlike within the prokaryotic cell, within the eukaryotic cell the genome has bulk. It has structure. 
It has contour and conformation. This characteristic arises as a result of the presence of chromosomal 
proteins [34,36,37]. Within this milieu resides an assortment of actors, including general transcription 
factors, DNA and RNA polymerases, and recruited chromosomal protein modifying enzymes. But our 
focus here will be on the role of the histone complex—especially histone H1.  
The compacted structure of heterochromatin and the loose open structure of euchromatin have been 
repeatedly studied, as well as the dynamic transformation of closed compacted DNA to a more open 
accessible state during transcription and DNA replication [35,100]. Although it is quite clear that the 
octamer nucleosome core complex serves as a scaffold during this process, the dynamic and specific 
role of histone H1 along with the post-translational modifications of the histone complex are still under 
intense study. Accumulated data continues to reveal the two functional aspects of chromatin modification 
which include effects that directly alter chromatin packing perhaps by a change in electrostatic charge, 
or an alteration of the nucleosome surface characteristics and DNA contour which could promote the 
recruitment  of  effector  protein  complexes.  The  latter  phenomenon  suggests  that  the  creation  of 
―epigenetic‖ marks could serve as perhaps signposts recognized by transcription activators and the 
associated effector protein complex [33,40,59]. Not only do modifications of the histone proteins play 
a role during transcription, but also the alterations of DNA as well. The relevance of the status of DNA 
methylation is evident in the altered patterns of DNA methylation found in neoplasia [58]. But it is Int. J. Mol. Sci. 2012, 13               
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proposed here that aberrant alterations of the DNA methylation patterns seen in neoplasia are not a 
reflection of the specific mechanism for the regulation of eukaryotic genes [101]. Altered patterns of 
DNA methylation seen in neoplasia more likely are a reflection of the methylation alterations induced 
in the setting of gene control gone wild as a direct result of the activity of a vital oncogene during its 
usurpation. In essence, hypermethylation and the inappropriate transcriptional silencing of genes is a 
response  to  oncogene  activity.  This  ―shutting-down‖  of  genes  probably  includes  especially  tumor 
suppressor genes. It is a way by which vital oncogenes may suppress the suppressors.  
The phosphorylation of linker histone H1 achieves the regulation of gene expression by mimicking 
H1 removal from compacted chromatin, resulting in decondensation and promoter gene exposure to 
the transcriptional complex [41,42]. Furthermore, site-specific interphase H1 phosphorylation facilitates 
transcription by RNA polymerases I and II [102] (Figure 2). It also appears that H1 phosphorylation 
regulates the ATP-dependent chromatin remodeling enzymes in a global fashion [103]. The cell cycle 
control protein CDK2 in turn phosphorylates histone H1 [104]. We can now visualize the completion 
of the cell growth cycle starting with the activation of the CDKs, followed by deactivation of pRb, then 
phosphorylation of histone H1, with subsequent decondensation of the chromatin complex, and finally 
phosphorylation-mediated activation of polymerases. As expected, the phosphorylation of histone H1 
plays a vital role in carcinogenesis including transformation caused by c-myc [60–62]. 
5. c-Myc a Prototype Vital Oncogene 
A vital oncogene must have certain fundamental characteristics. It must have a proven association 
with  cancer.  Its  direct  effect  must  occur  within  the  nucleus.  Its  oncoprotein  product  must  be  a 
downstream target for any associated initiating protein kinase cascade. Its oncoprotein product must 
usurp or alter normal cell cycle control mechanisms. Finally, there should be clinical evidence of 
oncogene addiction. c-Myc fulfills these criteria. The capacity of overexpressed c-myc to initiate and 
facilitate  proliferation,  and  its  association  with  diverse  cancers  is  incontrovertible  [105–107]. 
Accumulated research over the prior decade has increasingly confirmed the effect of c-myc on cell 
cycle regulation. It appears that c-myc has an effect on the frequency of initiation of the cell cycle. It 
affects the decision of cells to enter or exit the cell cycle [108,109]. Repression of c-myc in cycling 
cells causes arrest in G1 as a result of the reduction of cyclin E/CDK2 kinase activity [110]. Additional 
evidence has revealed the relevant genomic targets of the c-Myc oncoprotein [111]. Most revealing, 
however, is the differential genetic modulation and activation of CDK4/6, CDK2 and associated cyclin 
proteins by c-Myc [112–115]. Finally, the c-Myc oncoprotein directly interacts with the Rb suppressor 
protein  [116].  The  cell  cycle  effect  of  other  potential  vital  oncogenes  has  been  demonstrated  as  
well [117,118]. 
Although c-myc effects, no doubt, are mediated to some extent through direct gene activation of cell 
regulatory target genes we cannot exclude a direct effect of the c-Myc oncoprotein on the cell cycle 
control  cyclin  dependent  kinases  and  pRb.  The  binding  of  Tax  oncoprotein  of  the  human  T-cell 
leukemia  virus  type  I  to  CDK4  directly  stimulates  the  phosphorylation  of  pRb  [119].  Direct 
phosphorylation of CDK4 by the Src family of kinases occurs [120]. Here, it is proposed that vital 
oncogenes  function  by  facilitating  the  phosphorylation  of  vital  proteins  involved  in  human  gene Int. J. Mol. Sci. 2012, 13               
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regulation. These include the cyclin dependent kinases CDK 4/6 and CDK2, the Rb suppressor protein, 
histone H1 and the DNA and RNA polymerases (Figure 2). 
6. Conclusion 
There has been a less than silent revolution in cancer care for more than sixty years, starting with 
the initial growth factor research by Levi-Montalcini and Cohen [121]. This work has led directly to 
the  identification  of  the  functional  characteristics  of  cell  growth  factor  receptors  and  their  
associated receptor protein kinase cascades, as well as to the discovery of therapeutic protein kinase 
inhibitors [122–125]. This is the evolution of truly targeted cancer therapy. Phenomenal clinical results 
have been achieved in lung cancer and melanoma therapy [126,127]. The next revolution will be in the 
personalization of cancer care directed by utilization of targeted molecular therapies. Thus far the term 
targeted  therapy  has  been  applied  to  drugs  that  are  designed  to  inhibit  predominantly  signal 
transduction pathways thought to be critical for cancer cell growth and survival. However, there is a 
shortcoming to this approach. The difficulty results from our inability to identify which molecular 
target in any given cascade is the truly sentinel entity standing as the most important effector of the 
neoplastic process. This difficulty is evident when we look more closely at the overall clinical benefit 
of our current biologically targeted cancer therapies [128]. Ideal cancer targets must be molecules that 
are vital to the malignant phenotype. These entities must not be significantly expressed in a normal 
fashion in all other tissues. Aberrantly functioning transcription activators could fulfill this role [129]. 
There are considerably more human oncogenes in signaling pathways than oncogenic transcription 
activators. Still, obviously, there has to be a selective disruption of the transcription process. Here, it is 
proposed that vital oncogenes are rational targets for achieving personalized cancer care. The next 
great obstacle is how to go about identifying such entities. 
Cancer  results  from  a  deranged  genome  manifested  by  the  commonly  seen  associated  genetic 
defects, and evident in the resulting dysfunctional protein products of these defective genes that drive 
the cancer process. Advanced diagnostic techniques capable of detecting and reading genomic and 
proteomic information in an efficient, sensitive, and specific way will be the foundation upon which 
individualized cancer treatment will stand. Two evolving technologies will fulfill these criteria [43]. 
Genome-wide association studies of cancer have identified many important regions of genetic variation 
associated  with  cancer  [130,131].  The  technique  of  DNA  microarray  analysis,  a  high-throughput 
Southern blot technique, allows comparative assessment of genomic mutations, polymorphisms, and 
epigenetic alterations [45]. Analysis of gene expression profiles may help identify a host of potential 
vital oncogenes [132,133]. This investigative approach may help to identify not only new genome 
associated cancer markers, but will lead directly to development of specific drugs targeting the gene 
products of these gene candidates [134]. As this technology evolves, it may achieve the capacity to 
effectively  identify  specific  vital-oncogene  associated  gene  expression  patterns.  Therefore,  gene 
expression signature evaluations by DNA microarray techniques will allow a new way of molecularly 
classifying cancers, adding important information needed to determine the probability that a specific 
cancer  will  respond  to  a  specific  therapy  directed  against  the  vital  oncogene  driving  the  gene 
expression pattern seen in that particular cancer [135–137]. Int. J. Mol. Sci. 2012, 13               
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There also exists another potential footprint of vital oncogene activity. This will be evident within 
the  aberrant  and  specific  protein  patterns  detected  by  proteomic  techniques  [47].  Although  mass 
spectrometry is too crude for the ultimate specificity desired, even this approach reveals potential 
tumor  associated  signaling  proteins  in  cancer  cell  lines  [49].  More  relevant  is  the  capacity  to 
demonstrate a cancer’s dependence upon a specific transduction pathway [138]. Even more exciting is 
the ability to potentially identify a vital oncogene by comparative proteomic analysis [139]. Yet, even 
this is insufficient. We desire a specific, clinically feasible, and applicable approach that will identify 
the specific gene product of a vital oncogene. That specificity can be achieved by phosphoproteomic 
techniques, particularly utilizing antibody based methods [53,54,140]. Ultimately, however, nanofluidic 
proteomic assay analysis which is based upon the effect that post-translational modifications have on a 
protein’s  isoelectric  point  will  supersede  all  of  these  efforts.  This  method  allows  quantitation  of  
low-abundance protein isoforms in nanoliter volumes. For example, quantitation of the vital oncoproteins 
produced  by  the  vital  oncogenes  c-myc,  stat-3,  and  c-jun  has  been  demonstrated  [141].  Figure  3 
summarizes the diagnostic approaches that will serve as the foundation for the development of truly 
individualized cancer therapy. 
Figure 3. Diagnostic approaches used to evaluate vital oncogene action. 
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